The MDMA Therapy Training Program has launched a series of trainings to prepare therapy providers to become eligible to work on an MDMA-assisted psychotherapy for PTSD protocol.
The MDMA Therapy Training for Communities of Color event took place August 10-17, 2019, in Louisville, Kentucky, and was led by Marcela Ot’alora M.A., L.P.C., and Monnica Williams, Ph.D., A.B.P.P., with additional support. This event began with a 1.5-day Psychedelic Medicine and Cultural Trauma Community Workshop that was open to the public and was followed by a six-day training retreat for therapy providers who work with communities of color. In addition to twelve full scholarships for therapists and affiliated community organizers, tiered tuition pricing options were offered to the entire cohort. These scholarships were made possible through generous funding from the Open Society Foundation (OSF), Libra Foundation, Riverstyx Foundation, Psychedelic Science Funders Collaborative (PSFC), and Dr. Bronner’s. Additional scholarship programs are under development.
Our next MDMA Therapy Training Program retreat will take place October 1-8, 2019 in Asheville, North Carolina, and be led by Annie Mithoefer, B.S.N., and Michael Mithoefer, M.D. Future training retreats will be announced through the training newsletter as they are scheduled.
In January 2019, MAPS Public Benefit Corporation (MAPS PBC) submitted an MDMA-assisted psychotherapy for PTSD protocol to the U.S. Food and Drug Administration (FDA) as part of an application to participate in the FDA Expanded Access (EA) program. We’ve received and responded to several rounds of comments from FDA regarding our protocol submission for Expanded Access (EA), and we will likely hear from the FDA next month. The Expanded Access program’s purpose is to grant access to potentially beneficial investigational treatments for individuals or populations facing a serious or immediately life-threatening condition for which there is no satisfactory treatment currently available. If approved, MAPS PBC would likely start with a limited number of qualified sites to provide MDMA-assisted psychotherapy for participants with treatment-resistant PTSD under a MAPS PBC protocol.
Sites in the U.S. and U.S. territories interested in being considered to participate in an MDMA/PTSD protocol may now apply with MAPS PBC to assess eligibility and obtain the prerequisite training to administer MDMA-assisted psychotherapy. The basic requirements of a qualified site are 1) treatment facility conducive to MDMA-assisted psychotherapy, 2) therapy team, qualified and able to complete MDMA Therapy Training Program, and 3) prescribing physician who can obtain a DEA Schedule I license for MDMA.
Sites in the U.S. and U.S. territories interested in being considered to participate in an MDMA/PTSD protocol may now apply with MAPS PBC to assess eligibility and obtain the prerequisite training to administer MDMA-assisted psychotherapy. The basic requirements of a qualified site are 1) treatment facility conducive to MDMA-assisted psychotherapy, 2) therapy team, qualified and able to complete MDMA Therapy Training Program, and 3) prescribing physician who can obtain a DEA Schedule I license for MDMA.
Additional site and practitioner requirements are posted on our website. Each site must submit one site questionnaire and all applicants interested in training need to complete a therapy training application for providers. Only applicants affiliated with a qualifying site can be considered for training at this time. MAPS PBC will review applications on an ongoing basis, as they are received.
Sign up and stay tuned to the Training Program Newsletter to receive updates on upcoming trainings. • Learn More